Answers are grounded in this paper and cite their sources.
Most real-world tissue samples from patients with advanced cancer desiring CGP are limited, requiring optimized CGP approaches to produce meaningful results. An optimized PCR-CGP test, coupled with an inclusive exception testing policy, delivered reportable results for > 94% of samples, potentially expanding the proportion of CGP-testable patients and impact of biomarker-guided therapies.
No takes yet. Share an insight, caveat, or question.
Tomlins et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: